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Cancer  
Repositioned to kill stem cells 
 
Chemotherapy-resistant cancer stem cells preclude cure to many forms of the disease. 
Repositioning an existing drug to tackle this problem could significantly improve treatment 
for one form of leukaemia. See Letter p.XXX 
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In most cases of chronic myeloid leukaemia (CML), a daily oral medication rapidly 
transforms a progressive and ultimately fatal cancer into a chronic, but manageable condition. 
But this is not a cure. The persistence of quiescent (dormant, non-cycling) and thus drug-
resistant leukaemic stem cells (LSCs) represents an unmet clinical challenge in CML, and 
any attempt at cure must specifically target the eradication of these cells. In a paper published 
on Nature’s website today, Prost et al.1 present provocative pre-clinical and early clinical 
findings demonstrating that a drug currently used for diabetes therapy can be repositioned to 
target a pathway controlling quiescence in LSCs, causing the gradual erosion of this cellular 
pool.  
 
CML arises in a normal blood stem cell as a result of a mutation that involves an exchange of 
genetic material between chromosomes 9 and 22. This translocation creates the cancer-
driving gene known as BCR-ABL1, which produces a protein with enhanced activity as a 
tyrosine kinase enzyme, leading to uncontrolled cell proliferation. BCR-ABL1 has been 
shown to be sufficient to drive the development of leukaemia in mouse models2, and the 
discovery of this protein led to the development of tyrosine kinase inhibitors (TKIs) for CML 
treatment.  
 
Over the past two decades, TKIs have dramatically improved the outcome for patients with 
this cancer. Most patients presenting with early disease respond rapidly to TKI therapy and 
go into long-lasting remission. However, TKIs fail to eradicate LSCs, the cells that initiate 
and maintain CML, and these drug-resistant cells can drive relapse, or evolve to cause further 
forms of TKI resistance and more aggressive disease. As a result, patients on life-long TKI 
therapy are exposed to associated, often serious, side effects and may cease to respond to the 
treatment at any time. Furthermore, the significantly improved survival for patients on TKIs 
means that disease prevalence is increasing each year, with inherent social and economic 
implications.  
 
Several potential mechanisms to explain the insensitivity of LSCs to TKIs have been 
proposed, among which cellular quiescence seems to be key. Prost et al. describe that 
quiescence in LSCs is regulated by a pathway involving the receptor PPAR³ , the 
transcription factors STAT5 and HIF2α, and the protein CITED2, known as a master 
regulator of blood stem cell quiescence (Fig. 1). A particular strength of the study was the use 
of primary blood stem cells (expressing the marker CD34) from patients with CML to dissect 
the pathway and confirm the role of each component in regulating LSC quiescence.  
 
The authors go on to show that combining imatinib, the standard TKI used to manage CML, 
with the antidiabetic agent pioglitazone, which activates  PPAR³ , blocks this pathway in 
CML cells. The synergistic effects of the drugs reduce STAT5 expression and activity, 
downregulate HIF2± and CITED2 expression, and trigger the death of quiescent LSCs. 
Although the mechanism by which LSCs are killed in response to this drug combination is 
not clear, it is probable that they are either directly killed or driven to exit quiescence, which 
may predispose them to being eradicated by the TKI. The authors also demonstrate that the 
compound JQ1, a bromodomain inhibitor with broad activity that includes suppression of 
STAT5 activity, is as effective as pioglitazone (in combination with imatinib). Although this 
finding supports the role for the STAT5 pathway in LSC quiescence, the door is still open for 
studies of other agents that may target LSCs through this or alternative pathways. 
 
Collectively, these results strengthen the concept that cancer stem cells exhibit vulnerabilities 
in otherwise normal molecular pathways that may be targeted in a selective manner to 
achieve cure. Earlier work has demonstrated that CML stem cell quiescence is in part 
maintained by the promyelocytic leukaemia tumour-suppressor protein, which can be 
targeted by arsenic trioxide3, and that the cellular catabolic process of autophagy functions as 
a survival pathway for CML stem cells that can be targeted by the repositioning of the 
antimalarial agent hydroxychloroquine4 (Fig. 1). Both of these approaches are currently under 
investigation in the clinic.  
 
Prost el al. also tested the addition of pioglitazone to imatinib therapy in three patients with 
CML, and found that the patients converted from having demonstrable residual leukaemia to 
being disease-free, and that this effect lasted for months to years after pioglitazone 
withdrawal. These data provided a strong rationale for a phase 2 clinical trial, which started 
in July 2009 (ACTIM EudraCT 2009-011675-79). Although the interim results from this trial 
are encouraging, the study is non-randomised and it will therefore be difficult to ascertain 
definitively that improved response rates are driven by pioglitazone. 
 
Despite the need for further clinical testing of this particular combination therapy, Prost et al. 
have demonstrated the substantial potential for drug repositioning in CML research. Their 
results follow a recent report5 in which axitinib, a TKI approved for the treatment of drug-
resistant renal cell cancer, was repositioned for tackling TKI resistance in CML. Drugs that 
are already approved for other purposes can shorten the drug-development pathway by 5-10 
years and reduce risks and costs.  
 
Although drug repositioning can be somewhat serendipitous, Prost and colleagues had a 
tangible rationale that PPAR³  activators, such as pioglitazone, warranted investigation in 
CML, based on observed activity against a cell-line model of the disease [ok?]. Around 30% 
of newly approved drugs are already repositioned, and such hypothesis-driven repositioning 
strategies are likely to become more commonplace in cancer drug discovery. And this figure 
is set to rise further as our understanding of cellular pathways and processes increases and we 
include innovative computational approaches to facilitate disease-, drug- and treatment-
oriented drug repositioning. It is clear that repositioning will increasingly help the fast-
tracking of drugs into the clinic. As demonstrated by Prost and colleagues, this could soon 
signal the beginning of the end for stem cell quiescence in CML and other cancers.  
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Figure 1 | Targeting leukaemic stem cells in chronic myeloid leukaemia.  Prost et al.1 
describe a molecular pathway, involving the receptor PPARγ, the transcription factors 
STAT5 and HIF2α and the regulatory protein CITED2, that induces leukaemic stem cells 
(LSC) to enter a dormant (quiescent) state. They also show that the drug pioglitazone, which 
activates PPARγ and is approved for treating diabetes, can kill these cells when used in 
conjunction with tyrosine kinase inhibitors (TKIs), which are the standard therapy against 
active (cycling) leukaemic cells. Several additional drugs used to treat other diseases, 
axitinib, arsenic trioxide and hydroxychloroquine, have also been repositioned for use in 
treating chronic myeloid leukaemia, but demonstrate alternative mechanisms of action. 
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